DDInter1291 DDInter1376
Nifedipine, or BAY a 1040, is a first generation dihydropyridine L-type calcium channel blocker, similar to [nicardipine].[A190210,A190273,A175390,L11383] Nifedipine was developed by Bayer and first described in the literature, along with other dihydropyridines, in 1972.[A175390,A190276] Since nifedipine's development, second and third generation dihydropyridines have been developed with slower onsets and longer durations of action. The most popular of the third generation dihydropyridines is [amlodipine]. Nifedipine was granted FDA approval on 31 December 1981.
Ozanimod is a once-daily sphingosine 1-phosphate receptor modulator for the treatment of relapsing Multiple Sclerosis (MS) and inflammatory bowel disease. It was developed by Celgene (now acquired by Bristol-Myers Squibb) and was approved by the FDA on March 26, 2020.[L12573,L12582] The US approval was followed by the approval in Canada on October 2, 2020. In November 2021, ozanimod was also approved by the European Commission for the treatment of adults with relapsing remitting multiple sclerosis.[L39377,L39382] MS is a devastating inflammatory disease that often progresses and causes severe neurological, physical, and cognitive effects. Inflammatory bowel disease also a chronic inflammatory condition and can cause persistent abdominal pain, diarrhea, bloody stools, and vomiting. In clinical trials, Ozanimod has been shown to be well-tolerated and has resulted in a higher decrease in the rate of MS relapses than with intramuscular [interferon beta-1a], a current standard in MS therapy. Studies involving patients with inflammatory bowel disease have also shown promising results.[A189318,A189342]
Nifedipine {u} (Compound) resembles {v} (Compound) Isradipine
Nifedipine {u} (Compound) resembles {v} (Compound) Nicardipine
Nifedipine {u} (Compound) treats {v} (Disease) hypertension
Nifedipine {u} (Compound) binds {v} (Gene) CALM1
Nifedipine {u} (Compound) upregulates {v} (Gene) MTHFD2
Nifedipine {u} (Compound) palliates {v} (Disease) systemic scleroderma
Nifedipine {u} (Compound) is included by {v} (Pharmacologic Class) Dihydropyridines
Nifedipine {u} (Compound) downregulates {v} (Gene) FOXO4
Nifedipine {u} (Compound) causes {v} (Side Effect) Sleep disorder
Nifedipine {u} may cause a minor interaction that can limit clinical effects when taken with {v} Darolutamide
Nifedipine (Compound) resembles Isradipine (Compound)
Nifedipine (Compound) resembles Nicardipine (Compound)
Nifedipine (Compound) treats hypertension (Disease)
Nifedipine (Compound) binds CALM1 (Gene)
Nifedipine (Compound) upregulates MTHFD2 (Gene)
Nifedipine (Compound) palliates systemic scleroderma (Disease)
Nifedipine (Compound) is included by Dihydropyridines (Pharmacologic Class)
Nifedipine (Compound) downregulates FOXO4 (Gene)
Nifedipine (Compound) causes Sleep disorder (Side Effect)
Nifedipine may cause a minor interaction that can limit clinical effects when taken with Darolutamide